LANCET NEUROLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Neurology, 20(12), 1027-1037. Lancet Publishing Group PROPEL Study Group 2021, ' Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL) : an international, randomised, double-blind, parallel-group, phase 3 trial ', The Lancet Neurology, vol. 20, no. 12, pp. 1027-1037 . https://doi.org/10.1016/S1474-4422(21)00331-8
Siddiqi, Z A, Nowak, R J, Mozaffar, T, O'Brien, F, Yountz, M, Patti, F, Mazia, C G, Wilken, M, Wilken, M, Barroso, F, Saba, J, Rugiero, M, Bettini, M, Chaves, M, Vidal, G, Garcia, A D, De Bleecker, J, Van den Abeele, G, de Koning, K, De Mey, K, Mercelis, R, Mahieu, D, Wagemaekers, L, Van Damme, P, Depreitere, A, Schotte, C, Smetcoren, C, Stevens, O, Van Daele, S, Vandenbussche, N, Vanhee, A, Verjans, S, Vynckier, J, D'Hont, A, Tilkin, P, de Siqueira Carvalho, A A, Brockhausen, I D, Feder, D, Ambrosio, D, César, P, Melo, A P, Ribeiro, R M, Rocha, R, Rosa, B B, Andersen, H, Vissing, J, Højgaard, J, Witting, N, Pedersen, J, Weiss, M & The REGAIN Study Group 2021, ' Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab : subgroup analysis of REGAIN and its extension study ', Muscle and Nerve, vol. 64, no. 6, pp. 662-669 . https://doi.org/10.1002/mus.27422 Muscle & nerve, 64(6), 662-669. John Wiley and Sons Inc.